Does the media refer more to SLDB or MGNX?

In the previous week, Solid Biosciences had 3 more articles in the media than MacroGenics. MarketBeat recorded 7 mentions for Solid Biosciences and 4 mentions for MacroGenics. Solid Biosciences' average media sentiment score of 0.89 beat MacroGenics' score of 0.47 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MacroGenics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MGNX or AVTX?

In the previous week, Avalo Therapeutics had 6 more articles in the media than MacroGenics. MarketBeat recorded 10 mentions for Avalo Therapeutics and 4 mentions for MacroGenics. Avalo Therapeutics' average media sentiment score of 0.83 beat MacroGenics' score of 0.47 indicating that Avalo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avalo Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend MGNX or CVAC?

MacroGenics currently has a consensus price target of $6.33, indicating a potential upside of 55.04%. Given MacroGenics' stronger consensus rating and higher possible upside, equities analysts plainly believe MacroGenics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MacroGenics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, MGNX or CVAC?

CureVac has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MacroGenics $175.14M 1.49 -$74.62M -$0.22 N/A CureVac $70.74M 14.78 $175.50M $0.72 6.47

Is MGNX or CVAC more profitable?

CureVac has a net margin of 199.92% compared to MacroGenics' net margin of -8.70%. CureVac's return on equity of -23.03% beat MacroGenics' return on equity. Company Net Margins Return on Equity Return on Assets MacroGenics -8.70% -109.26% -18.70% CureVac 199.92% -23.03% -19.09%

Does the media favor SANA or MGNX?

In the previous week, Sana Biotechnology had 6 more articles in the media than MacroGenics. MarketBeat recorded 10 mentions for Sana Biotechnology and 4 mentions for MacroGenics. Sana Biotechnology's average media sentiment score of 0.59 beat MacroGenics' score of 0.47 indicating that Sana Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MacroGenics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ABUS or MGNX?

In the previous week, MacroGenics had 2 more articles in the media than Arbutus Biopharma. MarketBeat recorded 4 mentions for MacroGenics and 2 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.76 beat MacroGenics' score of 0.47 indicating that Arbutus Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MacroGenics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

MacroGenics (MGNX) Competitors

$4.08 -0.12 (-2.74%)

As of 02:27 PM Eastern

Compare

MGNX vs. SLDB, AVTX, CVAC, SANA, and ABUS

Should you buy MacroGenics stock or one of its competitors? MacroGenics's main competitors and comparable companies include Solid Biosciences (SLDB), Avalo Therapeutics (AVTX), CureVac (CVAC), Sana Biotechnology (SANA), and Arbutus Biopharma (ABUS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MacroGenics compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and MacroGenics (NASDAQ:MGNX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

In the previous week, Solid Biosciences had 3 more articles in the media than MacroGenics. MarketBeat recorded 7 mentions for Solid Biosciences and 4 mentions for MacroGenics. Solid Biosciences' average media sentiment score of 0.89 beat MacroGenics' score of 0.47 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MacroGenics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Solid Biosciences has a beta of 2.44, suggesting that its stock price is 144% more volatile than the broader market. Comparatively, MacroGenics has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market.

Solid Biosciences has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. Solid Biosciences' return on equity of -71.35% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
MacroGenics	-8.70%	-109.26%	-18.70%

MacroGenics has higher revenue and earnings than Solid Biosciences. MacroGenics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
MacroGenics	$175.14M	1.49	-$74.62M	-$0.22	N/A

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by insiders. Comparatively, 13.6% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Solid Biosciences presently has a consensus target price of $18.75, suggesting a potential upside of 123.35%. MacroGenics has a consensus target price of $6.33, suggesting a potential upside of 55.04%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Solid Biosciences is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Summary

Solid Biosciences beats MacroGenics on 9 of the 15 factors compared between the two stocks.

How does MacroGenics compare to Avalo Therapeutics?

MacroGenics (NASDAQ:MGNX) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

96.9% of MacroGenics shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 13.6% of MacroGenics shares are held by company insiders. Comparatively, 4.5% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MacroGenics has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

Avalo Therapeutics has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. Avalo Therapeutics' return on equity of -58.03% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-8.70%	-109.26%	-18.70%
Avalo Therapeutics	N/A	-58.03%	-48.22%

MacroGenics presently has a consensus price target of $6.33, indicating a potential upside of 55.04%. Avalo Therapeutics has a consensus price target of $45.10, indicating a potential upside of 188.55%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Avalo Therapeutics is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

In the previous week, Avalo Therapeutics had 6 more articles in the media than MacroGenics. MarketBeat recorded 10 mentions for Avalo Therapeutics and 4 mentions for MacroGenics. Avalo Therapeutics' average media sentiment score of 0.83 beat MacroGenics' score of 0.47 indicating that Avalo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avalo Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

MacroGenics has higher revenue and earnings than Avalo Therapeutics. MacroGenics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$175.14M	1.49	-$74.62M	-$0.22	N/A
Avalo Therapeutics	$59K	14,207.41	-$78.26M	-$4.37	N/A

Summary

Avalo Therapeutics beats MacroGenics on 9 of the 16 factors compared between the two stocks.

How does MacroGenics compare to CureVac?

MacroGenics (NASDAQ:MGNX) and CureVac (NASDAQ:CVAC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

MacroGenics currently has a consensus price target of $6.33, indicating a potential upside of 55.04%. Given MacroGenics' stronger consensus rating and higher possible upside, equities analysts plainly believe MacroGenics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

MacroGenics has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

In the previous week, MacroGenics had 4 more articles in the media than CureVac. MarketBeat recorded 4 mentions for MacroGenics and 0 mentions for CureVac. MacroGenics' average media sentiment score of 0.47 beat CureVac's score of 0.00 indicating that MacroGenics is being referred to more favorably in the media.

Company	Overall Sentiment
MacroGenics	Neutral
CureVac	Neutral

CureVac has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$175.14M	1.49	-$74.62M	-$0.22	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

CureVac has a net margin of 199.92% compared to MacroGenics' net margin of -8.70%. CureVac's return on equity of -23.03% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-8.70%	-109.26%	-18.70%
CureVac	199.92%	-23.03%	-19.09%

96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by insiders. Comparatively, 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

MacroGenics beats CureVac on 9 of the 16 factors compared between the two stocks.

How does MacroGenics compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and MacroGenics (NASDAQ:MGNX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by company insiders. Comparatively, 13.6% of MacroGenics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sana Biotechnology has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market. Comparatively, MacroGenics has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market.

Sana Biotechnology presently has a consensus price target of $9.33, suggesting a potential upside of 197.43%. MacroGenics has a consensus price target of $6.33, suggesting a potential upside of 55.04%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, equities research analysts plainly believe Sana Biotechnology is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, Sana Biotechnology had 6 more articles in the media than MacroGenics. MarketBeat recorded 10 mentions for Sana Biotechnology and 4 mentions for MacroGenics. Sana Biotechnology's average media sentiment score of 0.59 beat MacroGenics' score of 0.47 indicating that Sana Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MacroGenics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MacroGenics has higher revenue and earnings than Sana Biotechnology. MacroGenics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A
MacroGenics	$175.14M	1.49	-$74.62M	-$0.22	N/A

Sana Biotechnology has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. Sana Biotechnology's return on equity of -103.02% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-103.02%	-39.16%
MacroGenics	-8.70%	-109.26%	-18.70%

Summary

Sana Biotechnology beats MacroGenics on 11 of the 16 factors compared between the two stocks.

How does MacroGenics compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and MacroGenics (NASDAQ:MGNX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

In the previous week, MacroGenics had 2 more articles in the media than Arbutus Biopharma. MarketBeat recorded 4 mentions for MacroGenics and 2 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.76 beat MacroGenics' score of 0.47 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
MacroGenics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arbutus Biopharma has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, MacroGenics has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

Arbutus Biopharma has a net margin of 84.22% compared to MacroGenics' net margin of -8.70%. Arbutus Biopharma's return on equity of 90.98% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	84.22%	90.98%	82.34%
MacroGenics	-8.70%	-109.26%	-18.70%

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by insiders. Comparatively, 13.6% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Arbutus Biopharma currently has a consensus target price of $5.00, suggesting a potential downside of 0.89%. MacroGenics has a consensus target price of $6.33, suggesting a potential upside of 55.04%. Given MacroGenics' higher probable upside, analysts plainly believe MacroGenics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Arbutus Biopharma has higher earnings, but lower revenue than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	70.98	-$33.50M	$0.79	6.39
MacroGenics	$175.14M	1.49	-$74.62M	-$0.22	N/A

Summary

Arbutus Biopharma beats MacroGenics on 10 of the 16 factors compared between the two stocks.

Get MacroGenics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGNX vs. The Competition

Export

Metric	MacroGenics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$260.21M	$3.83B	$7.17B	$14.37B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-18.57	14.18	273.42	25.34
Price / Sales	1.49	1,546.01	675.88	98.52
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	4.64	15.26	10.41	6.21
Net Income	-$74.62M	-$22.78M	$3.49B	$358.18M
7 Day Performance	-5.44%	-2.44%	-1.96%	-1.36%
1 Month Performance	-3.20%	0.39%	-0.23%	-3.42%
1 Year Performance	161.86%	38.83%	19.03%	5.98%

MacroGenics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGNX MacroGenics	2.1759 of 5 stars	$4.09 -2.7%	$6.33 +55.0%	+164.2%	$260.21M	$175.14M	N/A	293
SLDB Solid Biosciences	2.5732 of 5 stars	$9.93 -3.1%	$18.18 +83.1%	+62.2%	$1.06B	N/A	N/A	100	News Coverage Analyst Forecast
AVTX Avalo Therapeutics	3.461 of 5 stars	$19.71 +2.5%	$45.10 +128.8%	+51.9%	$1.06B	$60K	N/A	40	Analyst Downgrade
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880
SANA Sana Biotechnology	2.8834 of 5 stars	$3.45 -10.4%	$9.33 +170.5%	-0.6%	$1.03B	N/A	N/A	380

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGNX) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MacroGenics (MGNX) Competitors

MGNX vs. SLDB, AVTX, CVAC, SANA, and ABUS

How does MacroGenics compare to Solid Biosciences?

Summary

How does MacroGenics compare to Avalo Therapeutics?

Summary

How does MacroGenics compare to CureVac?

Summary

How does MacroGenics compare to Sana Biotechnology?

Summary

How does MacroGenics compare to Arbutus Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX vs. The Competition

MacroGenics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MacroGenics (MGNX) Competitors

MGNX vs. SLDB, AVTX, CVAC, SANA, and ABUS

How does MacroGenics compare to Solid Biosciences?

Does the media refer more to SLDB or MGNX?

Which has more risk & volatility, SLDB or MGNX?

Is SLDB or MGNX more profitable?

Which has better earnings & valuation, SLDB or MGNX?

Do insiders and institutionals hold more shares of SLDB or MGNX?

Do analysts recommend SLDB or MGNX?

Summary

How does MacroGenics compare to Avalo Therapeutics?

Do insiders and institutionals have more ownership in MGNX or AVTX?

Which has more volatility and risk, MGNX or AVTX?

Is MGNX or AVTX more profitable?

Do analysts recommend MGNX or AVTX?

Does the media refer more to MGNX or AVTX?

Which has stronger valuation & earnings, MGNX or AVTX?

Summary

How does MacroGenics compare to CureVac?

Do analysts recommend MGNX or CVAC?

Which has more volatility & risk, MGNX or CVAC?

Does the media refer more to MGNX or CVAC?

Which has higher valuation and earnings, MGNX or CVAC?

Is MGNX or CVAC more profitable?

Do institutionals & insiders believe in MGNX or CVAC?

Summary

How does MacroGenics compare to Sana Biotechnology?

Do institutionals & insiders hold more shares of SANA or MGNX?

Which has more risk and volatility, SANA or MGNX?

Do analysts rate SANA or MGNX?

Does the media favor SANA or MGNX?

Which has better earnings and valuation, SANA or MGNX?

Is SANA or MGNX more profitable?

Summary

How does MacroGenics compare to Arbutus Biopharma?

Does the media favor ABUS or MGNX?

Which has more risk & volatility, ABUS or MGNX?

Is ABUS or MGNX more profitable?

Do insiders & institutionals hold more shares of ABUS or MGNX?

Do analysts prefer ABUS or MGNX?

Which has stronger valuation and earnings, ABUS or MGNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX vs. The Competition

MacroGenics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools